Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04943224Phase 2Recruiting

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Role: collaborator

NCT04943198Phase 2Recruiting

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Role: collaborator

NCT04943211Phase 3Recruiting

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Role: collaborator

NCT07194720Not ApplicableCompleted

Effects of the Cornelian Cherry Supplementation on the Selected Physiological Parameters in Marathon Runners

Role: collaborator

All 4 trials loaded